Abstract:Objective To explore the long-term effects of risk-based stratification treatment of children with medulloblastoma and elucidate the relationship between risk factors,treatment effects and prognosis.Methods Patients admitted from January 2010 to June 2015 with primary medulloblastoma confirmed by postoperative histopathology were stratified into low-risk or high-risk group.They were stratified on the basis of risk factors,i.e.age,Chang et al's staging system (no metastasis M0,with metastasis M +),complete/near total tumor resection and postoperative residue tumor (tumor residue ≥ 1.5 cm).pathological type (classical medulloblastoma CMB,desmoplastic medulloblastoma DMB,medulloblastoma with extensive nodularity MBEN,large cell medulloblastoma LCMB and anaplatic medulloblastoma AMB).The low-risk group (＞3 years,M0,complete/near total tumor resection,CMB,DMB/MBEN) received postoperative 24～30 Gy craniospinal irradiation followed by a boost of 54～56 Gy to tumor bed in posterior fossa and then 8 cycles of sequential maintenance chemotherapy.In the high-risk group (≤3 years,M +,tumor residue ≥1.5 em,AMB/LCMB),children aged ＞3 years received two-cycles of postoperative induced chemotherapy,followed by 36 Gy craniospinal irradiation and then a boost of 54～56Gy to tumor bed in posterior fossa,followed by 4 cycles of maintenance chemotherapy after irradiation.Children aged ≤3 years received 3 cycles of postoperative induced chemotherapy followed by 4 cycles of maintenance chemotherapy.Results Among 115 children with histologically confirmed primary medulloblastoma,there were 77 boys and 38 girls with a male-to-female ratio of 2.02 ∶ 1.Eight cases were aged under 3 years and 107 cases older than 3.Therefore the median age was 6.75 years (15 months the youngest and 15 years the oldest).The lowrisk group had 60 children (accounting for 52.2％ of total) while 55 children (accounting for 47.8％) were put in high-risk group.The median follow-up period was 25 (6-60) months.The 3-5 year overall survival (OS) was 85.5％ in low-risk group versus 67.7％ in high-risk group.And significant difference existed between two groups (P＜0.05).In addition,3-5 year disease-free survival (DFS) was 76.8％ in low-risk group while 47.3％ in high-risk group.Two groups showed significant intergroup difference (P＜0.05).Among 31 recurrent cases (27.0％),twoof them were aged ≤3 years.The median time of postoperative recurrence was 12 months (4 weeks to 48 months).Among them,2 obtained complete remission and 13 patients showed partial remission.Another 16 patients died,including 1 patient aged ≤ 3 years.One case suffered secondary intracranial high-grade glioma.Conclusions For diagnosis and therapy stratified on the basis of risk-factors for children with medulloblastoma,survival ratio and quality of life may be improved.The long-term survival of such children has correlation with risk factors.

Effectiveness of metronomic chemotherapy in a child with medulloblastoma: A case report

Metronomic Chemotherapy for Pediatric Refractory Solid Tumors: A Retrospective Single-center Study

Clinical Characterization of Adult Medulloblastoma and the Effect of First-Line Therapies on Outcome; the MD Anderson Cancer Center Experience

MDB-87. REAL-LIFE EXPERIENCE WITH A “MEMMAT-LIKE” METRONOMIC REGIMEN FOR RELAPSED/REFRACTORY MEDULLOBLASTOMA

Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials

MODL-20. Metabolic rewiring support the onset of chemotherapy resistance in medulloblastoma

The Role of Chemotherapy in the Treatment of Adult Medulloblastoma

MDB-27. OUTCOMES FOR CHILDREN TREATED FOR MEDULLOBLASTOMA USING A RADIATION-SPARING APPROACH: A REPORT FROM THE CHILDREN’S BRAIN TUMOR NETWORK

Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience

Overcoming multiple drug resistance mechanisms in medulloblastoma

Analysis of the Personalized Treatment and the Relevant Prognostic Factors in Children with Medulloblastoma

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment

Characterization of Recurrence Patterns and Outcomes of Medulloblastoma in Adults: the University of Texas MD Anderson Cancer Center Experience

Abstract 5115: Designing targeted approaches for recurrent medulloblastoma

Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma

RARE-47. CHARACTERIZATION OF ADULT MEDULLOBLASTOMA; A RETROSPECTIVE REVIEW OF 200 PATIENTS AT MD ANDERSON CANCER CENTER

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma

Clinical and effect analyses of comprehensive treatment for medulloblastoma: a report of 115 children

MEDB-05. Survival and prognostic factors in childhood medulloblastoma: A China single center experience from 2006 to 2015

Treatment Barriers and Clinical Outcome of Children with Medulloblastoma in China: a Report from the Chinese Children's Cancer Group (CCCG).

MB-40THE 15 YEARS CLINICAL EXPERIENCE OF MULTIDISCIPLINARY TREATMENT FOR MEDULLOBLASTOMA IN CHILDREN: ANALYSIS OF 122 CASES